Navigation Links
New Research Offers Hope In Kidney FailureTreatment

An analysis of how two different proteins interact with one another to enable self destruction of kidney cells when there is an reduced oxygen supply// to the tissue may eventually pave way for improved treatment modalities to manage ischemic renal failure.

Such self-destruction of the kidney can be activated during dehydration, low blood pressure, injury to the kidney, removal of kidney during kidney transplantation and septic shock, all of which result in a temporary reduction or halt of blood and oxygen supply.

Ischemia, or reduced oxygen supply can trigger apopotosis or programmed cell death, more specifically in the tubular cells of the kidney that consume most of the energy. Ischemic kidney failure has been associated with a 50% mortality. Despite improvements in the medical field, it has not been possible to reduce this mortality rate associated with the disease, over the years.

Tubular cells are loaded with the task of reabsorbtion of nearly 50 gallons of fluid, in addition to substances such as salt and glucose, in a short span of 24 hours. These cells, therefore consume a high amount of energy and are highly susceptible to apoptosis and injury. In a oxygen starved state, two killer proteins termed Bid and Bax get activated and establish a partnership to induce cell death. This system is highly active in the kidney.

A $1 million grant has been sanctioned by the National Institute of Diabetes & Digestive & Kidney Diseases to the research group to better understand the role of these proteins in causing ischemic renal failure.

While it is known that during ischemic renal injury, the protein Bid is cleaved, followed by release of active fragments. It is not exactly known what causes the protein to cleave and move from its usual place outside the cell to mitochondria which is loacted inside the cell membrane. Cleavage of Bid yields a truncated Bid product (tBid) that may interact with Bax to produce a change in the protein structure.

This may further failitate the movemet of the Bax protein inside the mitochondria. Once inside, the protein can inhibit the respiratory function of the mitochondria, which is the main source of oxygen to the cells. The researchers believe that Bid and Bax exibit a synergistic activity to promote apoptosis or cell death. Without Bid, there is less apoptosis while kidney function and survival rates significantly improve. In addition, there is also an enhanced cell regeneration, paving way for ischemic recovery.

The researchers are currently studing the effect of kidney damage caused by Cisplatin, an anti-cancer agent used in the treatment of ovarian, testicular, small cell lung cancer and head and neck tumors. With our improved understanding of such concepts, we might perhaps have an improved treatment modality for ischemic renal failure and perhaps cancer by accelarating self-destruction.

'We want to see how the drug can kill kidney cells and if we can find a protective mechanism to prevent kidney cell death without stopping cancer cell death,' says Dr. Dong, one of the senoir researchers involved in the study.


'"/>




Related medicine news :

1. Kidney Stones - Interesting New Research implicates bacteria as its cause
2. Researchers urge caution in using ear tube surgery
3. Paracetamol May Cause Live Damage Warns Consumer Education and Research Centre
4. Researchers Scale to assess the Severity of Epilepsy in Kids
5. Research of Ritalin
6. Researchers trick Alzheimers Enzyme
7. Researchers find new HIV hiding place
8. A Compilation of recent Diabetes Research articles
9. Research on causes for falling helps develop preventive strategies
10. New standards for Human Research Safety
11. Research on Celiac Disease in children
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... 2017 , ... PurhealthRX , a leading Health and Nutrition Company, is ... to full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing ... easily incorporated into liquid products, while reducing costs to end users. , The team ...
(Date:10/13/2017)... ... , ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to ... unique items from across the nation, this holiday-themed event will raise funds and awareness ... VNA. The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 ...
(Date:10/13/2017)... , ... October 13, 2017 , ... ... and Agile Software Development, has been awarded a contract by the Center for ... Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in a ...
(Date:10/12/2017)... LA (PRWEB) , ... October 12, 2017 , ... Planet ... in the U.S., announced today its plans to open a flagship location in Covington, ... occupy the former Rooms To Go store next to Office Depot in the Holiday ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... Diplomat Pharmacy, Inc. (NYSE: DPLO ... LLC , and named its founder as Diplomat,s chief ... Tennessee , will operate under Diplomat subsidiary ... offerings for health care partners to include IT outsourcing, ... "In an interoperable world, technology delivers comprehensive insight ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, Inc. ... earnings conference call and webcast on Friday, November 3, ... (EDT) and ending at approximately 8:30 a.m. (CDT) / ... the company,s 2017 financial performance and guidance for 2018, ... initiatives to enhance operational performance, and long-range financial outlook ...
(Date:9/25/2017)... 25, 2017  EpiVax, Inc., a leader in ... immune-engineering today announced the launch of EpiVax Oncology ... personalized therapeutic cancer vaccines. EpiVax has provided $500,000 ... to enabling technologies to the new precision immunotherapy ... EpiVax Oncology as Chief Executive Officer. Gad brings ...
Breaking Medicine Technology: